| Name | Title | Contact Details |
|---|---|---|
Ted Lotchin |
Chief Compliance Officer | Profile |
Unison Risk Advisors is one of the top privately-held insurance brokerages in the nation. Through its regional operating companies, Unison Risk Advisors provides risk management services, commercial property and casualty insurance, employee benefits and health insurance, personal and life insurance, and retirement plan services to corporate and individual clients in a diverse set of industries. Unison Risk Advisors is committed to an independent brokerage service model guided by the belief that clients are best served by professionally managed and well-resourced firms that can act independently upon the best interests of the client.
The impact of disasters—natural or otherwise—can leave even the most robust entities vulnerable, causing uncertainty over their future. This constant threat magnifies stress, strains resources, and hampers growth, making resilience more crucial than ever. At Tidal Basin Group, we tackle these challenges head-on. As architects of resilience, we transform vulnerability into strength through innovative thinking and integrated solutions in program management, technology and emergency consulting. We listen, consider diverse perspectives, and equip you with the tools to redefine resilience. Our mission is to empower organizations and communities to rebound from challenges, and create a future where resilience is the backbone of every strategy—helping everyone to Be stronger than before®.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Grant Thornton una de las firmas líderes a nivel mundial de servicios profesionales de Auditoría, Consultoría de Negocio, Tecnología e Innovación y Asesoramiento Fiscal, Legal, Financiero, Laboral y Outsourcing. Pertenecemos a una de las organizaciones y red líderes en servicios profesionales en todo el mundo, Grant Thornton International, con más de 73.000 profesionales presentes en más de 147 mercados. En España contamos con un equipo multidisciplinar, transversal, con experiencia y visión empresarial, que da servicio a más de 4.000 clientes en 10 oficinas repartidas por el territorio nacional: Madrid, Barcelona, Bilbao, Castellón, Las Palmas, Murcia, Valencia, Pamplona y Zaragoza.